Cassava Sciences Alzheimer's disease therapy late-stage trial progress approved by DSMB
Cassava Sciences announced that its late-stage clinical trial for Alzheimer's disease has received approval from the Data and Safety Monitoring Board (DSMB) to continue without modification. The company's mid-term safety MRI data released in October 2023 indicated that simufilam is not associated with amyloid-related imaging abnormalities seen in treatment. This news has attracted attention from investment institutions and the medical community, leading to a more than 2% increase in the stock price during pre-market trading on the US stock market
According to the Zhitong Finance APP, Cassava Sciences (SAVA.US) announced that it has completed the third interim safety review of simufilam in an important late-stage clinical trial for the treatment of Alzheimer's disease patients.
It is understood that the Data and Safety Monitoring Board (DSMB) pre-review meeting recommended that Cassava Sciences continue the important Phase 3 clinical study as planned without any modifications.
This latest development today comes after the announcement of mid-term safety MRI data in October 2023, which indicated that simufilam under Cassava Sciences is not associated with amyloid-related imaging abnormalities seen during treatment.
Cassava Sciences is a biotechnology company based in Texas, USA, focusing on developing innovative drugs for the treatment of Alzheimer's disease. Its main research project includes a drug called simufilam, which aims to improve the cognitive abilities of Alzheimer's patients by restoring the normal structure and function of brain proteins.
Cassava Sciences' clinical trials for Alzheimer's disease treatment drugs have attracted widespread attention. The company's recent significant development involves the progress of simufilam in Phase 3 clinical trials, drawing high interest from investment institutions focused on biotechnology companies and the medical community. The success of these trials could bring potential breakthroughs in the treatment of Alzheimer's disease.
Benefiting from this positive news, the company's stock price rose over 2% in pre-market trading on the US stock market